282 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
5 Answers to Questions Gilead Sciences' Investors Probably Have https://www.fool.com/investing/2017/06/18/5-answers-to-questions-gilead-sciences-investors-p.aspx?source=iedfolrf0000001 Jun 18, 2017 - Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.
Gilead Sciences, Inc.: The Bear Case From a Bull https://www.fool.com/investing/2017/06/09/gilead-sciences-inc-the-bear-case-from-a-bull.aspx?source=iedfolrf0000001 Jun 09, 2017 - A pessimistic view of Gilead Sciences' prospects from a long-time fan of the big biotech.
Why Is NewLink Genetics Losing One-Third of Its Value Today? https://www.fool.com/investing/general/2017/06/08/why-is-newlink-genetics-losing-one-third-of-its-va.aspx?source=iedfolrf0000001 Jun 08, 2017 - Roche Holdings will no longer collaborate with NewLink Genetics on GDC-0919.
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda http://www.zacks.com/stock/news/266022/aduro-starts-phase-ii-combo-study-with-crs-207-keytruda?cid=CS-ZC-FT-266022 Jun 29, 2017 - Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months https://www.fool.com/investing/2017/07/15/3-stocks-that-turned-1000-into-at-least-2017-in-12.aspx?source=iedfolrf0000001 Jul 15, 2017 - You don't need a million bucks to have a winning portfolio.
Better Buy: Agenus Inc. vs. Kite Pharma https://www.fool.com/investing/2017/07/02/better-buy-agenus-inc-vs-kite-pharma.aspx?source=iedfolrf0000001 Jul 02, 2017 - Is Agenus or Kite Pharma the better oncology stock to own right now?
3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? https://www.fool.com/investing/2017/07/20/3-hottest-biotech-stocks-of-2017-are-they-still-bu.aspx?source=iedfolrf0000001 Jul 21, 2017 - Calthera Biosciences, Aurinia Pharmaceuticals, and Esperion Therapeutics are some of the hottest biotech stocks in 2017, and catalysts that are on deck could suggest there's more upside ahead.
3 Top Biotech Stocks Under $5 https://www.fool.com/investing/2017/08/19/3-top-biotech-stocks-under-5.aspx?source=iedfolrf0000001 Aug 19, 2017 - Shares of Geron Corporation, Rigel Pharmaceuticals Inc., and Agenus Inc. appear to be trading for much less than they could be worth.
3 Most Promising Cancer Drugs in Late-Stage Development https://www.fool.com/investing/2017/08/22/3-most-promising-cancer-drugs-in-late-stage-develo.aspx?source=iedfolrf0000001 Aug 22, 2017 - Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates.
Incyte Corp. (INCY) Rose To A 1-Month High On Baricitinib News http://www.rttnews.com/story.aspx?Id=2810097 Aug 31, 2017 - Incyte Corp. (INCY) and Eli Lilly & Co. (LLY) announced Wednesday morning that will resubmit the New Drug Application for baricitinib before the end of January 2018. The decision was made after discussions with the FDA.

Pages: 12345678910...29

<<<Page 5>